LHX vs REGN · P/E 34, rev $5.88B vs P/E 14, rev $4.29B
L3Harris Technologies Inc (LHX) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
L3Harris Technologies Inc (LHX) is a aerospace & defense company listed on US.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Latest reported LHX revenue for 2026-07-03 was $5.88B. Net income was $600.0M. Revenue was up 2.4% from 2026-04-03 to 2026-07-03. LHX currently screens at market cap $58.72B and trailing P/E 34.3.
Latest reported REGN revenue for 2026-06-30 was $4.29B. Net income was $1.30B. Revenue was up 19.0% from 2026-03-31 to 2026-06-30. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
LHX currently screens at market cap $58.72B and trailing P/E 34.3. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the LHX and REGN stock pages for the full models.
Not investment advice.